98556-62-8

Basic information

• Product Name: 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile
• Synonyms: 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile;2-oxo-2,3-dihydrobenzo[d]oxazole-6-carbonitrile;2-Oxo-2,3-dihydro-benzooxazole-6-carbonitrile
• CAS NO: 98556-62-8
• Molecular Formula: C₈H₄N₂O₂
• Molecular Weight: 160.12956
• Mol File: 98556-62-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.47±0.1 g/cm3(Predicted)
• PKA: 8.13±0.70(Predicted)
• CAS DataBase Reference: 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile(98556-62-8)
• EPA Substance Registry System: 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile(98556-62-8)

Safety Data

• Hazardous Substances Data: 98556-62-8(Hazardous Substances Data)

Usage

General Description

The chemical compound 2,3-dihydro-2-oxo-6-benzoxazolecarbonitrile, also known as benoxacor, is a benzoxazole-derived herbicide used to control annual grasses and certain broadleaf weeds in crops. It inhibits the growth of weeds by interfering with the synthesis of fatty acids and protein in the plant cells. Benoxacor is typically applied as an emulsifiable concentrate, and it is absorbed primarily through the roots of the target plants. It has been found to have low toxicity to mammals and is considered to have a favorable environmental profile compared to other herbicides. However, it is important to handle benoxacor with care and follow all safety precautions when using it.

Upstream product

• 19932-85-5 6-bromobenzo[d]oxazol-2(3H)-one 
• 14543-43-2 3-amino-4-hydroxybenzonitrile 
• 530-62-1 1,1'-carbonyldiimidazole 
• 773837-37-9 sodium cyanide 
• 55586-26-0 3-hydroxy-4-aminobenzonitrile 
• 544-92-3 copper(I) cyanide 
• 98949-53-2 3-acetyl-2-oxo-2,3-dihydro-benzoxazole-6-carbonitrile 

Downstream Products

• 1397706-38-5 C₁₈H₁₇N₃O 
• 54903-15-0 2-oxo-2,3-dihydro-1,3-benzoxazole-6-carbaldehyde 
• 1435049-12-9 trans-4-[[3-(6-formyl-2-oxo-1,3-benzoxazol-3(2H)-yl)propyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1435049-13-0 trans-4-[{3-[6-({[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-2-oxo-1,3-benzoxazol-3(2H)-yl]propyl} (methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1435519-04-2 trans-4-[{3-[6-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl] amino}methyl)-2-oxo-1,3-benzoxazol-3(2H)-yl]propyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1616455-82-3 (3R)-1-azabicyclo[2.2.2]oct-3-yl (4-{3-[6-({[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-2-oxo-1,3-benzoxazol-3(2H)-yl]propyl}biphenyl-2-yl)carbamate 
• 1616455-81-2 (3R)-1-azabicyclo[2.2.2]oct-3-yl(4-{(1E)-3-[6-({[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}methyl)-2-oxo-1,3-benzoxazol-3(2H)-yl]prop-1-en-1-yl}biphenyl-2-yl)carbamate 
• 1616455-80-1 (3R)-1-azabicyclo[2.2.2]oct-3-yl {4-[(1E)-3-(6-formyl-2-oxo-1,3-benzoxazol-3(2H)-yl)prop-1-en-1-yl]biphenyl-2-yl}carbamate 
• 1561763-62-9 (S)-2-oxo-N-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2,3-dihydrobenzo[d]oxazole-6-carboxamide 

Relevant articles and documents

NEW CYCLOHEXYL AND QUINUCLIDINYL CARBAMATE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITY

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.